A Phase 2 interventional study of Atezolizumab and Bevacizumab in Carcinoma, Non-Small-Cell Lung, sponsored by Hoffmann-La Roche. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 27 under way, 5 of them phase 3. atezolizumab · Carcinoma, Non-Small-Cell Lung.
Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 67th largest by enrollment, is one of 9 that started in 2020, is one of 48 in phase 2, and was the 53rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 6 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
EuroCityClinic LLC · Sites in Russia
Ages 18+
Fundación GECP · Sites in Spain
Ages 18+
By country, each count listing its studies:
atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, atezolizumab is the treatment under test here. Read study by study →
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 52 · Phase 3 19 · Phase 4 3
First in 2013; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 81 interventional studies. Of the 47 that completed or were terminated, 30 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 81 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche: 5 open now, 16 under way, 8 of them phase 3. Of 161 finished, 96 (60%) have results posted.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 122nd largest by enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2020, is one of 56 in phase 2, and was the 154th registered.
Hoffmann-La Roche’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2001.
10 of the studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT04302025Genentech, Inc.A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | 2026-11-30 |
| NCT03786692Fox Chase Cancer CenterPhase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | 2026-12 |
| NCT04691817Abramson Cancer Center at Penn MedicineTocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | 2026-12 |
| NCT05340309University of Southern CaliforniaSubcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Hoffmann-La Roche’s 182 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a sensitizing mutation in the EGFR gene must have experienced disease progression or were intolerant to treatment with one or more EGFR TKIs. Patients who have progressed on or were intolerant to osimertinib or other thirdgeneration EGFR TKIs are eligible.
Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs, and who have no evidence of the EGFR T790M mutation after TKI therapy are eligible.
Patients who have progressed on or were intolerant to first- or second-generation EGFR TKIs and who have evidence of the T790M mutation must have also progressed on or were intolerant to osimertinib to be eligible.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death.
Drug: Atezolizumab · Drug: Bevacizumab
Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
Also known as: Tecentriq
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Also known as: Avastin
Objective Response Rate (ORR)
Objective response rate (ORR) was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
Time frame: Baseline up to approximately 10 months
Duration of Objective Response (DOR)
Duration of objective response (DOR) was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
Time to Response (TTR)
Time to response (TTR) was defined as the time from the start of the treatment to the first objective tumor response observed for participants who achieved CR or PR, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
Disease Control Rate (DCR)
Disease control rate (DCR) was defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
Overall Survival (OS)
OS after enrollment was defined as the time from enrollment to death from any cause.
Time frame: Baseline until death due to any cause (up to approximately 2.5 years)
Progression-Free Survival (PFS)
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline up to approximately 2.5 years
PFS Rate at 6 and 12 Months
PFS rate at 6 and 12 months is defined as the percentage of participants who have not experienced disease progression or death from any cause at 6 and 12 months, as determined by the investigator according to RECIST v1.1.
Time frame: Baseline to 6 months and 12 months
OS Rate at 1 and 2 Years
OS rate at 1 and 2 years was defined as the percentage of participants who have not experienced death from any cause at 1 and 2 years.
Time frame: Baseline to 1 and 2 Years
Percentage of Participants With Adverse Events
Percentage of participants with adverse events.
Time frame: Baseline up to approximately 2.5 years
Percentage of Participants With Serious and Non-Serious Immune-Mediated Adverse Events (irAEs)
Percentage of serious and non-serious immune-mediated adverse events related to atezolizumab treatment. The AESIs were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. The grading is as follows: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE.
Time frame: Baseline up to approximately 2.5 years
Objective Response Rate (ORR) According to iRECIST
Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to Modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 2.5 years
Disease Control Rate (DCR) According to iRECIST
Disease control rate (DCR) is defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to 2 years and approximately 5 months
Duration of Objective Response (DOR) According to iRECIST
Duration of objective response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 2.5 years
Progression-Free Survival (PFS) According to iRECIST
Progression-free survival (PFS) is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 2.5 years
Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST
Progression-free survival (PFS) rate is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first at 12 months, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
Time frame: Baseline up to approximately 12 months
Time to Deterioation (TTD) Using EORTC
Time to deterioration (TTD) using European Organization for Research and treatment of Cancer (EORTC) Quality-of-life Questionnaire Core 30 (QLQ C30) and its Lung Cancer Module (QLQ LC13) is defined as the time from baseline to the first time the patient's score shows a \>=10 points increase above baseline in any of the following EORTC-transformed symptom subscale scores (whichever occurs first): cough, dyspnoea (single item), dyspnoea (multi-item subscale), chest pain, or arm/shoulder pain, whichever occurred first. Scores ranged from 0-10. A higher score represented more severe symptoms.
Time frame: Baselsine up to approximately 1 year
Change From Baseline in Health-Related Quality of Life (HRQoL) and Health Status
The 30-item EORTC QLQ-C30 version 3 is composed by five multi-item function scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), six single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), and a two-item global quality of life scale. All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for the functional and general health areas represent better functional status and quality of life. Higher scores for the symptom scales represent more symptoms or problems (poor quality of life). A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.
Time frame: Baseline up to approximately 1 year
Change From Baseline in Lung Cancer Related Symptoms
The EORTC QLQ-LC13 is a specific module for lung cancer. It consists of 13 items covering lung cancer symptoms (dyspnoea, coughing, hemoptysis, pain in chest, pain in arm or shoulder and pain in other parts) and the side effects of chemo- and radiotherapy (alopecia, peripheral neuropathy, sore mouth, and dysphagia), which are divided into 10 fields, all are symptom types. All EORTC symptom scores are linearly transformed so that each score has a range of 0-100. A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.
Time frame: Baseline up to approximately 1 year
This study was conducted at multiple investigational sites in China
| Milestone | Atezolizumab Plus Bevacizumab |
|---|---|
| Started | 23 |
| Completed | 0 |
| Not completed | 23 |
| Withdrew: Death | 17 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Study terminated by sponsor | 5 |
Objective response rate (ORR) was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
| Percentage of Participants | Atezolizumab Plus Bevacizumab |
|---|---|
| Objective Response Rate (ORR) | 18.2 (5.19 to 40.28) |
Duration of objective response (DOR) was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to RECIST v1.1.
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Duration of Objective Response (DOR) | 6.36 (2.66 to NA) |
Time to response (TTR) was defined as the time from the start of the treatment to the first objective tumor response observed for participants who achieved CR or PR, as determined by the investigator according to RECIST v1.1.
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Time to Response (TTR) | 1.577 ± 0.490 |
Disease control rate (DCR) was defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to RECIST v1.1.
| Percentage of Participants | Atezolizumab Plus Bevacizumab |
|---|---|
| Disease Control Rate (DCR) | 65.2 (42.73 to 83.62) |
OS after enrollment was defined as the time from enrollment to death from any cause.
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Overall Survival (OS) | 14.06 (8.80 to 22.14) |
Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Progression-Free Survival (PFS) | 2.76 (1.35 to 4.07) |
PFS rate at 6 and 12 months is defined as the percentage of participants who have not experienced disease progression or death from any cause at 6 and 12 months, as determined by the investigator according to RECIST v1.1.
| Percentage of participants | Atezolizumab Plus Bevacizumab |
|---|---|
| 6 months | 13.91 (3.49 to 31.36) |
| 12 months | 4.64 (0.33 to 19.26) |
OS rate at 1 and 2 years was defined as the percentage of participants who have not experienced death from any cause at 1 and 2 years.
| Percentage of participants | Atezolizumab Plus Bevacizumab |
|---|---|
| 1 year | 52.17 (30.51 to 70.01) |
| 2 years | 30.43 (13.54 to 49.28) |
Percentage of participants with adverse events.
| Participants | Atezolizumab Plus Bevacizumab |
|---|---|
| Percentage of Participants With Adverse Events | 23 |
Percentage of serious and non-serious immune-mediated adverse events related to atezolizumab treatment. The AESIs were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria. The grading is as follows: Grade 1=Mild AE, Grade 2=Moderate AE, Grade 3=Severe AE, Grade 4=Life-threatening or disabling AE, Grade 5=Death related to AE.
| Participants | Atezolizumab Plus Bevacizumab |
|---|---|
| Non-serious irAEs | 7 |
| Serious irAEs | 1 |
Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to Modified RECIST v1.1 (iRECIST).
| Percentage of Participants | Atezolizumab Plus Bevacizumab |
|---|---|
| Objective Response Rate (ORR) According to iRECIST | 17.4 (4.95 to 38.78) |
Disease control rate (DCR) is defined as the proportion of participants who have a best overall response of CR or PR or stable disease (SD), as determined by the investigator according to modified RECIST v1.1 (iRECIST).
| Percentage of Participants | Atezolizumab Plus Bevacizumab |
|---|---|
| Disease Control Rate (DCR) According to iRECIST | 65.2 (42.73 to 83.62) |
Duration of objective response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Duration of Objective Response (DOR) According to iRECIST | 6.36 (2.66 to NA) |
Progression-free survival (PFS) is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Progression-Free Survival (PFS) According to iRECIST | 2.76 (1.35 to 4.07) |
Progression-free survival (PFS) rate is defined as the time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first at 12 months, as determined by the investigator according to modified RECIST v1.1 (iRECIST).
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Progression-Free Survival (PFS) Rate at 12 Months According to iRECIST | 4.64 (0.33 to 19.26) |
Time to deterioration (TTD) using European Organization for Research and treatment of Cancer (EORTC) Quality-of-life Questionnaire Core 30 (QLQ C30) and its Lung Cancer Module (QLQ LC13) is defined as the time from baseline to the first time the patient's score shows a \>=10 points increase above baseline in any of the following EORTC-transformed symptom subscale scores (whichever occurs first): cough, dyspnoea (single item), dyspnoea (multi-item subscale), chest pain, or arm/shoulder pain, whichever occurred first. Scores ranged from 0-10. A higher score represented more severe symptoms.
| Months | Atezolizumab Plus Bevacizumab |
|---|---|
| Cough | NA (3.48 to NA) |
| Dyspnoea (single-item Q33) | NA (NA to NA) |
| Dyspnoea (single-item Q34) | NA (NA to NA) |
| Dyspnoea (single-item Q35) | NA (NA to NA) |
| Dyspnoea (multi-item) | NA (NA to NA) |
| Chest pain | NA (2.10 to NA) |
| Arm/shoulder pain | NA (NA to NA) |
The 30-item EORTC QLQ-C30 version 3 is composed by five multi-item function scales (physical, role, cognitive, emotional, and social), three multi-item symptom scales (fatigue, nausea and vomiting, and pain), six single-item symptom scales (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), and a two-item global quality of life scale. All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for the functional and general health areas represent better functional status and quality of life. Higher scores for the symptom scales represent more symptoms or problems (poor quality of life). A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.
| Units on a scale | Atezolizumab Plus Bevacizumab |
|---|---|
| Global Quality of Life (QoL) - Baseline | 53.409 ± 28.132 |
| Global QoL - Treatment Cycle 02 | 0.833 ± 28.855 |
| Global QoL - Treatment Cycle 03 | -0.521 ± 27.465 |
| Global QoL - Treatment Cycle 04 | -6.250 ± 28.007 |
| Global QoL - Treatment Cycle 05 | -15.625 ± 24.975 |
| Global QoL - Treatment Cycle 06 | -16.667 ± 23.987 |
| Global QoL - Treatment Cycle 07 | -23.611 ± 20.012 |
| Global QoL - Treatment Cycle 08 | -20.833 ± 43.381 |
| Global QoL - Treatment Cycle 09 | -36.111 ± 4.811 |
| Global QoL - Treatment Cycle 10 | -22.222 ± 19.245 |
| Global QoL - Treatment Cycle 11 | -30.556 ± 4.811 |
| Global QoL - Treatment Cycle 12 | -27.778 ± 9.623 |
| Global QoL - Treatment Cycle 13 | -33.333 ± NA |
| Global QoL - Treatment Cycle 14 | -25.000 ± 11.785 |
| Global QoL - Treatment Cycle 15 | -33.333 ± 0.000 |
| Global QoL - Follow Up | -16.667 ± NA |
| Global QoL - Follow Up 2 | -16.667 ± NA |
| Global QoL - Follow Up 3 | -25.000 ± NA |
| Physical Functioning - Baseline | 79.091 ± 15.437 |
| Physical Functioning - Treatment Cycle 02 | -5.667 ± 20.207 |
| Physical Functioning - Treatment Cycle 03 | -4.167 ± 15.490 |
| Physical Functioning - Treatment Cycle 04 | -0.556 ± 11.177 |
| Physical Functioning - Treatment Cycle 05 | -1.667 ± 14.584 |
| Physical Functioning - Treatment Cycle 06 | -0.833 ± 10.947 |
| Physical Functioning - Treatment Cycle 07 | -6.667 ± 10.328 |
| Physical Functioning - Treatment Cycle 08 | -8.889 ± 10.037 |
| Physical Functioning - Treatment Cycle 09 | -15.556 ± 16.777 |
| Physical Functioning - Treatment Cycle 10 | -6.667 ± 6.667 |
| Physical Functioning - Treatment Cycle 11 | -6.667 ± 6.667 |
| Physical Functioning - Treatment Cycle 12 | -13.333 ± 17.638 |
| Physical Functioning - Treatment Cycle 13 | -6.667 ± NA |
| Physical Functioning - Treatment Cycle 14 | -6.667 ± 9.428 |
| Physical Functioning - Treatment Cycle 15 | 0.000 ± 0.000 |
| Physical Functioning - Follow Up | 0.000 ± NA |
| Physical Functioning - Follow Up 2 | 6.667 ± NA |
| Physical Functioning - Follow Up 3 | 0.000 ± NA |
| Role Functioning - Baseline | 81.061 ± 22.593 |
| Role Functioning - Treatment Cycle 02 | -7.500 ± 32.307 |
| Role Functioning - Treatment Cycle 03 | -7.292 ± 28.525 |
| Role Functioning - Treatment Cycle 04 | -4.167 ± 14.434 |
| Role Functioning - Treatment Cycle 05 | -4.167 ± 21.362 |
| Role Functioning - Treatment Cycle 06 | -4.167 ± 14.773 |
| Role Functioning - Treatment Cycle 07 | 0.000 ± 21.082 |
| Role Functioning - Treatment Cycle 08 | -8.333 ± 25.276 |
| Role Functioning - Treatment Cycle 09 | -11.111 ± 19.245 |
| Role Functioning - Treatment Cycle 10 | -11.111 ± 9.623 |
| Role Functioning - Treatment Cycle 11 | 0 ± 0 |
| Role Functioning - Treatment Cycle 12 | -5.556 ± 9.623 |
| Role Functioning - Treatment Cycle 13 | 0.000 ± NA |
| Role Functioning - Treatment Cycle 14 | 0.000 ± 0.000 |
| Role Functioning - Treatment Cycle 15 | 0.000 ± 0.000 |
| Role Functioning - Follow Up | 0.000 ± NA |
| Role Functioning - Follow Up 2 | 0.000 ± NA |
| Role Functioning - Follow Up 3 | 0.000 ± NA |
| Emotional Functioning - Baseline | 76.894 ± 23.561 |
| Emotional Functioning - Treatment Cycle 02 | -2.083 ± 18.312 |
| Emotional Functioning - Treatment Cycle 03 | -0.521 ± 20.965 |
| Emotional Functioning - Treatment Cycle 04 | 0.000 ± 28.868 |
| Emotional Functioning - Treatment Cycle 05 | -5.208 ± 23.544 |
| Emotional Functioning - Treatment Cycle 06 | -4.167 ± 19.920 |
| Emotional Functioning - Treatment Cycle 07 | -12.500 ± 22.822 |
| Emotional Functioning - Treatment Cycle 08 | -8.333 ± 15.811 |
| Emotional Functioning - Treatment Cycle 09 | -13.889 ± 17.347 |
| Emotional Functioning - Treatment Cycle 10 | -16.667 ± 14.434 |
| Emotional Functioning - Treatment Cycle 11 | -19.444 ± 26.788 |
| Emotional Functioning - Treatment Cycle 12 | -2.778 ± 12.729 |
| Emotional Functioning - Treatment Cycle 13 | 0.000 ± NA |
| Emotional Functioning - Treatment Cycle 14 | 4.167 ± 5.893 |
| Emotional Functioning - Treatment Cycle 15 | 4.167 ± 5.893 |
| Emotional Functioning - Follow Up | 0.000 ± NA |
| Emotional Functioning - Follow Up 2 | 0.000 ± NA |
| Emotional Functioning - Follow Up 3 | 0.000 ± NA |
| Cognitive Functioning - Baseline | 79.545 ± 17.006 |
| Cognitive Functioning - Treatment Cycle 02 | 1.667 ± 17.014 |
| Cognitive Functioning - Treatment Cycle 03 | -2.083 ± 14.751 |
| Cognitive Functioning - Treatment Cycle 04 | 1.389 ± 15.006 |
| Cognitive Functioning - Treatment Cycle 05 | -8.333 ± 17.817 |
| Cognitive Functioning - Treatment Cycle 06 | 2.083 ± 13.909 |
| Cognitive Functioning - Treatment Cycle 07 | -16.667 ± 25.820 |
| Cognitive Functioning - Treatment Cycle 08 | -11.111 ± 17.213 |
| Cognitive Functioning - Treatment Cycle 09 | -5.556 ± 9.623 |
| Cognitive Functioning - Treatment Cycle 10 | 5.556 ± 9.623 |
| Cognitive Functioning - Treatment Cycle 11 | 0.000 ± 0.000 |
| Cognitive Functioning - Treatment Cycle 12 | -5.556 ± 9.623 |
| Cognitive Functioning - Treatment Cycle 13 | 0.000 ± NA |
| Cognitive Functioning - Treatment Cycle 14 | 0.000 ± 0.000 |
| Cognitive Functioning - Treatment Cycle 15 | -8.333 ± 11.785 |
| Cognitive Functioning - Follow Up | 0.000 ± NA |
| Cognitive Functioning - Follow Up 2 | 0.000 ± NA |
| Cognitive Functioning - Follow Up 3 | 0.000 ± NA |
| Social Functioning - Baseline | 67.424 ± 28.857 |
| Social Functioning - Treatment Cycle 02 | -3.333 ± 30.874 |
| Social Functioning - Treatment Cycle 03 | 1.042 ± 25.436 |
| Social Functioning - Treatment Cycle 04 | -1.389 ± 28.831 |
| Social Functioning - Treatment Cycle 05 | 0.000 ± 34.503 |
| Social Functioning - Treatment Cycle 06 | 2.083 ± 32.657 |
| Social Functioning - Treatment Cycle 07 | -13.889 ± 24.553 |
| Social Functioning - Treatment Cycle 08 | -11.111 ± 25.092 |
| Social Functioning - Treatment Cycle 09 | -11.111 ± 25.459 |
| Social Functioning - Treatment Cycle 10 | -11.111 ± 9.623 |
| Social Functioning - Treatment Cycle 11 | -11.111 ± 9.623 |
| Social Functioning - Treatment Cycle 12 | -5.556 ± 19.245 |
| Social Functioning - Treatment Cycle 13 | 16.667 ± NA |
| Social Functioning - Treatment Cycle 14 | -8.333 ± 35.355 |
| Social Functioning - Treatment Cycle 15 | -8.333 ± 35.355 |
| Social Functioning - Follow Up | 0.000 ± NA |
| Social Functioning - Follow Up 2 | 0.000 ± NA |
| Social Functioning - Follow Up 3 | -33.333 ± NA |
| Fatigue - Baseline | 34.343 ± 22.979 |
| Fatigue - Treatment Cycle 02 | 3.889 ± 25.814 |
| Fatigue - Treatment Cycle 03 | 8.333 ± 20.488 |
| Fatigue - Treatment Cycle 04 | 5.556 ± 24.845 |
| Fatigue - Treatment Cycle 05 | 8.333 ± 17.568 |
| Fatigue - Treatment Cycle 06 | 9.722 ± 13.849 |
| Fatigue - Treatment Cycle 07 | 9.259 ± 12.989 |
| Fatigue - Treatment Cycle 08 | 16.667 ± 18.257 |
| Fatigue - Treatment Cycle 09 | 14.815 ± 16.973 |
| Fatigue - Treatment Cycle 10 | 14.815 ± 16.973 |
| Fatigue - Treatment Cycle 11 | 18.519 ± 32.075 |
| Fatigue - Treatment Cycle 12 | 7.407 ± 23.130 |
| Fatigue - Treatment Cycle 13 | 0.000 ± NA |
| Fatigue - Treatment Cycle 14 | 0.000 ± 0.000 |
| Fatigue - Treatment Cycle 15 | 5.556 ± 7.857 |
| Fatigue - Follow Up | 0.000 ± NA |
| Fatigue - Follow Up 2 | -33.333 ± NA |
| Fatigue - Follow Up 3 | -33.333 ± NA |
| Nausea and Vomiting - Baseline | 6.818 ± 15.985 |
| Nausea and Vomiting - Treatment Cycle 02 | 2.500 ± 9.786 |
| Nausea and Vomiting - Treatment Cycle 03 | 3.125 ± 12.500 |
| Nausea and Vomiting - Treatment Cycle 04 | 0.000 ± 7.107 |
| Nausea and Vomiting - Treatment Cycle 05 | 2.083 ± 5.893 |
| Nausea and Vomiting - Treatment Cycle 06 | 0.000 ± 0.000 |
| Nausea and Vomiting - Treatment Cycle 07 | 0.000 ± 0.000 |
| Nausea and Vomiting - Treatment Cycle 08 | 2.778 ± 6.804 |
| Nausea and Vomiting - Treatment Cycle 09 | 0.000 ± 0.000 |
| Nausea and Vomiting - Treatment Cycle 10 | 0.000 ± 0.000 |
| Nausea and Vomiting - Treatment Cycle 11 | 0.000 ± 0.000 |
| Nausea and Vomiting - Treatment Cycle 12 | 0.000 ± 0.000 |
| Nausea and Vomiting - Treatment Cycle 13 | 0.000 ± NA |
| Nausea and Vomiting - Treatment Cycle 14 | 0.000 ± 0.000 |
| Nausea and Vomiting - Treatment Cycle 15 | 0.000 ± 0.000 |
| Nausea and Vomiting - Follow Up | 0.000 ± NA |
| Nausea and Vomiting - Follow Up 2 | 0.000 ± NA |
| Nausea and Vomiting - Follow Up 3 | 0.000 ± NA |
| Pain - Baseline | 31.061 ± 24.286 |
| Pain -Treatment Cycle 02 | -2.500 ± 23.116 |
| Pain -Treatment Cycle 03 | -4.167 ± 21.517 |
| Pain -Treatment Cycle 04 | -1.389 ± 18.060 |
| Pain -Treatment Cycle 05 | 6.250 ± 23.465 |
| Pain -Treatment Cycle 06 | 4.167 ± 24.801 |
| Pain -Treatment Cycle 07 | 5.556 ± 17.213 |
| Pain -Treatment Cycle 08 | 16.667 ± 29.814 |
| Pain -Treatment Cycle 09 | 27.778 ± 34.694 |
| Pain -Treatment Cycle 10 | 5.556 ± 9.623 |
| Pain -Treatment Cycle 11 | 22.222 ± 19.245 |
| Pain -Treatment Cycle 12 | 11.111 ± 19.245 |
| Pain -Treatment Cycle 13 | 0.000 ± NA |
| Pain -Treatment Cycle 14 | 8.333 ± 11.785 |
| Pain -Treatment Cycle 15 | 16.667 ± 23.570 |
| Pain - Follow Up | 0.000 ± NA |
| Pain - Follow Up 2 | -16.667 ± NA |
| Pain - Follow Up 3 | -16.667 ± NA |
| Dyspnoea - Baseline | 25.758 ± 22.845 |
| Dyspnoea - Treatment Cycle 02 | 3.333 ± 30.397 |
| Dyspnoea - Treatment Cycle 03 | 6.250 ± 21.837 |
| Dyspnoea - Treatment Cycle 04 | 2.778 ± 17.164 |
| Dyspnoea - Treatment Cycle 05 | 8.333 ± 15.430 |
| Dyspnoea - Treatment Cycle 06 | 12.500 ± 17.252 |
| Dyspnoea - Treatment Cycle 07 | 5.556 ± 13.608 |
| Dyspnoea - Treatment Cycle 08 | 11.111 ± 17.213 |
| Dyspnoea - Treatment Cycle 09 | 33.333 ± 0.000 |
| Dyspnoea - Treatment Cycle 10 | 11.111 ± 19.245 |
| Dyspnoea - Treatment Cycle 11 | 11.111 ± 19.245 |
| Dyspnoea - Treatment Cycle 12 | 11.111 ± 19.245 |
| Dyspnoea - Treatment Cycle 13 | 33.333 ± NA |
| Dyspnoea - Treatment Cycle 14 | 16.667 ± 23.570 |
| Dyspnoea - Treatment Cycle 15 | 16.667 ± 23.570 |
| Dyspnoea - Follow Up | 0.000 ± NA |
| Dyspnoea - Follow Up 2 | 0.000 ± NA |
| Dyspnoea - Follow Up 3 | -33.333 ± NA |
| Insomnia - Baseline | 27.273 ± 22.150 |
| Insomnia - Treatment Cycle 02 | 5.000 ± 29.170 |
| Insomnia - Treatment Cycle 03 | 6.250 ± 27.806 |
| Insomnia - Treatment Cycle 04 | 0.000 ± 24.618 |
| Insomnia - Treatment Cycle 05 | 4.167 ± 27.817 |
| Insomnia - Treatment Cycle 06 | 8.333 ± 29.547 |
| Insomnia - Treatment Cycle 07 | 5.556 ± 25.092 |
| Insomnia - Treatment Cycle 08 | 0.000 ± 29.814 |
| Insomnia - Treatment Cycle 09 | 11.111 ± 19.245 |
| Insomnia - Treatment Cycle 10 | 11.111 ± 19.245 |
| Insomnia - Treatment Cycle 11 | 22.222 ± 19.245 |
| Insomnia - Treatment Cycle 12 | 11.111 ± 19.245 |
| Insomnia - Treatment Cycle 13 | 0.000 ± NA |
| Insomnia - Treatment Cycle 14 | 0.000 ± 0.000 |
| Insomnia - Treatment Cycle 15 | 16.667 ± 23.570 |
| Insomnia - Follow Up | 0.000 ± NA |
| Insomnia - Follow Up 2 | 0.000 ± NA |
| Insomnia - Follow Up 3 | 0.000 ± NA |
| Appetite Loss - Baseline | 27.273 ± 24.422 |
| Appetite Loss - Treatment Cycle 02 | -1.667 ± 29.568 |
| Appetite Loss - Treatment Cycle 03 | -6.250 ± 27.806 |
| Appetite Loss - Treatment Cycle 04 | 2.778 ± 22.285 |
| Appetite Loss - Treatment Cycle 05 | 4.167 ± 21.362 |
| Appetite Loss - Treatment Cycle 06 | 4.167 ± 21.362 |
| Appetite Loss - Treatment Cycle 07 | -5.556 ± 13.608 |
| Appetite Loss - Treatment Cycle 08 | 0.000 ± 21.082 |
| Appetite Loss - Treatment Cycle 09 | -11.111 ± 19.245 |
| Appetite Loss - Treatment Cycle 10 | 0.000 ± 33.333 |
| Appetite Loss - Treatment Cycle 11 | 11.111 ± 19.245 |
| Appetite Loss - Treatment Cycle 12 | -11.111 ± 19.245 |
| Appetite Loss - Treatment Cycle 13 | 0.000 ± NA |
| Appetite Loss - Treatment Cycle 14 | 16.667 ± 23.570 |
| Appetite Loss - Treatment Cycle 15 | 16.667 ± 23.570 |
| Appetite Loss - Follow Up | 33.333 ± NA |
| Appetite Loss - Follow Up 2 | 0.000 ± NA |
| Appetite Loss - Follow Up 3 | 0.000 ± NA |
| Constipation - Baseline | 15.152 ± 16.988 |
| Constipation - Treatment Cycle 02 | -3.333 ± 23.939 |
| Constipation - Treatment Cycle 03 | 6.250 ± 30.353 |
| Constipation - Treatment Cycle 04 | -5.556 ± 12.975 |
| Constipation - Treatment Cycle 05 | -4.167 ± 21.362 |
| Constipation - Treatment Cycle 06 | -8.333 ± 15.430 |
| Constipation - Treatment Cycle 07 | -5.556 ± 13.608 |
| Constipation - Treatment Cycle 08 | -5.556 ± 13.608 |
| Constipation - Treatment Cycle 09 | -11.111 ± 19.245 |
| Constipation - Treatment Cycle 10 | 0.000 ± 33.333 |
| Constipation - Treatment Cycle 11 | 11.111 ± 19.245 |
| Constipation - Treatment Cycle 12 | 0.000 ± 33.333 |
| Constipation - Treatment Cycle 13 | 33.333 ± NA |
| Constipation - Treatment Cycle 14 | 0.000 ± 0.000 |
| Constipation - Treatment Cycle 15 | 16.667 ± 23.570 |
| Constipation - Follow Up | 0.000 ± NA |
| Constipation - Follow Up 2 | 0.000 ± NA |
| Constipation - Follow Up 3 | 0.000 ± NA |
| Diarrhoea - Baseline | 9.091 ± 18.349 |
| Diarrhoea - Treatment Cycle 02 | -3.333 ± 18.417 |
| Diarrhoea - Treatment Cycle 03 | -4.167 ± 20.638 |
| Diarrhoea - Treatment Cycle 04 | -8.333 ± 20.719 |
| Diarrhoea - Treatment Cycle 05 | -4.167 ± 11.785 |
| Diarrhoea - Treatment Cycle 06 | -4.167 ± 11.785 |
| Diarrhoea - Treatment Cycle 07 | -5.556 ± 13.608 |
| Diarrhoea - Treatment Cycle 08 | 0.000 ± 21.082 |
| Diarrhoea - Treatment Cycle 09 | -11.111 ± 19.245 |
| Diarrhoea - Treatment Cycle 10 | -11.111 ± 19.245 |
| Diarrhoea - Treatment Cycle 11 | 0.000 ± 33.333 |
| Diarrhoea - Treatment Cycle 12 | -11.111 ± 19.245 |
| Diarrhoea - Treatment Cycle 13 | 0.000 ± NA |
| Diarrhoea - Treatment Cycle 14 | 0.000 ± 0.000 |
| Diarrhoea - Treatment Cycle 15 | 16.667 ± 23.570 |
| Diarrhoea - Follow Up | 0.000 ± NA |
| Diarrhoea - Follow Up 2 | 0.000 ± NA |
| Diarrhoea - Follow Up 3 | 0.000 ± NA |
| Financial Difficulties - Baseline | 60.606 ± 33.549 |
| Financial Difficulties - Treatment Cycle 02 | -8.333 ± 26.213 |
| Financial Difficulties - Treatment Cycle 03 | -10.417 ± 26.440 |
| Financial Difficulties - Treatment Cycle 04 | -11.111 ± 25.950 |
| Financial Difficulties - Treatment Cycle 05 | -16.667 ± 25.198 |
| Financial Difficulties - Treatment Cycle 06 | -33.333 ± 30.861 |
| Financial Difficulties - Treatment Cycle 07 | -27.778 ± 32.773 |
| Financial Difficulties - Treatment Cycle 08 | -22.222 ± 40.369 |
| Financial Difficulties - Treatment Cycle 09 | -22.222 ± 50.918 |
| Financial Difficulties - Treatment Cycle 10 | -22.222 ± 50.918 |
| Financial Difficulties - Treatment Cycle 11 | -11.111 ± 50.918 |
| Financial Difficulties - Treatment Cycle 12 | -11.111 ± 50.918 |
| Financial Difficulties - Treatment Cycle 13 | -66.667 ± NA |
| Financial Difficulties - Treatment Cycle 14 | 0.000 ± 0.000 |
| Financial Difficulties - Treatment Cycle 15 | -16.667 ± 23.570 |
| Financial Difficulties - Follow Up | 0.000 ± NA |
| Financial Difficulties - Follow Up 2 | -33.333 ± NA |
| Financial Difficulties - Follow Up 3 | -33.333 ± NA |
The EORTC QLQ-LC13 is a specific module for lung cancer. It consists of 13 items covering lung cancer symptoms (dyspnoea, coughing, hemoptysis, pain in chest, pain in arm or shoulder and pain in other parts) and the side effects of chemo- and radiotherapy (alopecia, peripheral neuropathy, sore mouth, and dysphagia), which are divided into 10 fields, all are symptom types. All EORTC symptom scores are linearly transformed so that each score has a range of 0-100. A participant was classified as improved if a decrement of 10 points or worse was observed in the change from baseline scores. A participant was classified as worsened if a 10-point or greater increase was observed in the change from baseline scores.
| Units on a scale | Atezolizumab Plus Bevacizumab |
|---|---|
| Dyspnoea - Baseline | 34.343 ± 20.260 |
| Dyspnoea - Treatment Cycle 02 | -5.556 ± 18.557 |
| Dyspnoea - Treatment Cycle 03 | -2.778 ± 20.488 |
| Dyspnoea - Treatment Cycle 04 | -4.630 ± 16.723 |
| Dyspnoea - Treatment Cycle 05 | -2.778 ± 19.473 |
| Dyspnoea - Treatment Cycle 06 | 5.556 ± 16.798 |
| Dyspnoea - Treatment Cycle 07 | 0.000 ± 14.055 |
| Dyspnoea - Treatment Cycle 08 | 0.000 ± 22.222 |
| Dyspnoea - Treatment Cycle 09 | 11.111 ± 0.000 |
| Dyspnoea - Treatment Cycle 10 | 7.407 ± 16.973 |
| Dyspnoea - Treatment Cycle 11 | 7.407 ± 6.415 |
| Dyspnoea - Treatment Cycle 12 | 7.407 ± 16.973 |
| Dyspnoea - Treatment Cycle 13 | 11.111 ± NA |
| Dyspnoea - Follow Up | -22.222 ± NA |
| Dyspnoea - Follow Up 2 | -22.222 ± NA |
| Dyspnoea - Follow Up 3 | -33.333 ± NA |
| Coughing - Baseline | 37.879 ± 31.363 |
| Coughing - Treatment Cycle 02 | 1.667 ± 25.305 |
| Coughing - Treatment Cycle 03 | 10.417 ± 23.472 |
| Coughing - Treatment Cycle 04 | 0.000 ± 14.213 |
| Coughing - Treatment Cycle 05 | 4.167 ± 21.362 |
| Coughing - Treatment Cycle 06 | 16.667 ± 30.861 |
| Coughing - Treatment Cycle 07 | 0.000 ± 21.082 |
| Coughing - Treatment Cycle 08 | 11.111 ± 34.427 |
| Coughing - Treatment Cycle 09 | 0.000 ± 0.000 |
| Coughing - Treatment Cycle 10 | -11.111 ± 19.245 |
| Coughing - Treatment Cycle 11 | -11.111 ± 19.245 |
| Coughing - Treatment Cycle 12 | -11.111 ± 19.245 |
| Coughing - Treatment Cycle 13 | 0.000 ± NA |
| Coughing - Treatment Cycle 14 | 0.000 ± 47.140 |
| Coughing - Treatment Cycle 15 | 0.000 ± 0.00 |
| Coughing - Follow Up | -33.333 ± NA |
| Coughing - Follow Up 2 | -33.333 ± NA |
| Coughing - Follow Up 3 | -66.667 ± NA |
| Hemoptysis - Baseline | 4.545 ± 15.585 |
| Hemoptysis - Treatment Cycle 02 | -1.667 ± 13.134 |
| Hemoptysis - Treatment Cycle 03 | -2.083 ± 8.333 |
| Hemoptysis - Treatment Cycle 04 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 05 | -4.167 ± 11.785 |
| Hemoptysis - Treatment Cycle 06 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 07 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 08 | 11.111 ± 27.217 |
| Hemoptysis - Treatment Cycle 09 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 10 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 11 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 12 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 13 | 0.000 ± NA |
| Hemoptysis - Treatment Cycle 14 | 0.000 ± 0.000 |
| Hemoptysis - Treatment Cycle 15 | 0.000 ± 0.000 |
| Hemoptysis - Follow Up | 0.000 ± NA |
| Hemoptysis - Follow Up 2 | 0.000 ± NA |
| Hemoptysis - Follow Up 3 | 0.000 ± NA |
| Sore mouth - Baseline | 3.030 ± 9.808 |
| Sore mouth - Treatment Cycle 02 | 6.667 ± 20.520 |
| Sore mouth - Treatment Cycle 03 | 4.167 ± 20.638 |
| Sore mouth - Treatment Cycle 04 | 0.000 ± 20.101 |
| Sore mouth - Treatment Cycle 05 | 4.167 ± 11.785 |
| Sore mouth - Treatment Cycle 06 | -4.167 ± 11.785 |
| Sore mouth - Treatment Cycle 07 | 5.556 ± 13.608 |
| Sore mouth - Treatment Cycle 08 | 5.556 ± 13.608 |
| Sore mouth - Treatment Cycle 09 | 0.000 ± 0.000 |
| Sore mouth - Treatment Cycle 10 | 0.000 ± 0.000 |
| Sore mouth - Treatment Cycle 11 | 0.000 ± 0.000 |
| Sore mouth - Treatment Cycle 12 | 0.000 ± 0.000 |
| Sore mouth - Treatment Cycle 13 | 0.000 ± NA |
| Sore mouth - Treatment Cycle 14 | 0.000 ± 0.000 |
| Sore mouth - Treatment Cycle 15 | 0.000 ± 0.000 |
| Sore mouth - Follow Up | 0.000 ± NA |
| Sore mouth - Follow Up 2 | 0.000 ± NA |
| Sore mouth - Follow Up 3 | 0.000 ± NA |
| Dysphagia - Baseline | 10.606 ± 15.891 |
| Dysphagia - Treatment Cycle 02 | 5.000 ± 24.839 |
| Dysphagia - Treatment Cycle 03 | 0.000 ± 12.172 |
| Dysphagia - Treatment Cycle 04 | -2.778 ± 9.623 |
| Dysphagia - Treatment Cycle 05 | 0.000 ± 0.000 |
| Dysphagia - Treatment Cycle 06 | -8.333 ± 15.430 |
| Dysphagia - Treatment Cycle 07 | -5.556 ± 13.608 |
| Dysphagia - Treatment Cycle 08 | -5.556 ± 13.608 |
| Dysphagia - Treatment Cycle 09 | -11.111 ± 19.245 |
| Dysphagia - Treatment Cycle 10 | -11.111 ± 19.245 |
| Dysphagia - Treatment Cycle 11 | -11.111 ± 19.245 |
| Dysphagia - Treatment Cycle 12 | -11.111 ± 19.245 |
| Dysphagia - Treatment Cycle 13 | 0.000 ± NA |
| Dysphagia - Treatment Cycle 14 | -16.667 ± 23.570 |
| Dysphagia - Treatment Cycle 15 | -16.667 ± 23.570 |
| Dysphagia - Follow Up | -33.333 ± NA |
| Dysphagia - Follow Up 2 | -33.333 ± NA |
| Dysphagia - Follow Up 3 | -33.333 ± NA |
| Peripheral neuropathy - Baseline | 9.091 ± 18.349 |
| Peripheral neuropathy - Treatment Cycle 02 | 6.5667 ± 23.195 |
| Peripheral neuropathy - Treatment Cycle 03 | 4.167 ± 16.667 |
| Peripheral neuropathy - Treatment Cycle 04 | 8.333 ± 15.076 |
| Peripheral neuropathy - Treatment Cycle 05 | 12.500 ± 17.252 |
| Peripheral neuropathy - Treatment Cycle 06 | 12.500 ± 17.252 |
| Peripheral neuropathy - Treatment Cycle 07 | 11.111 ± 17.213 |
| Peripheral neuropathy - Treatment Cycle 08 | 11.111 ± 17.213 |
| Peripheral neuropathy - Treatment Cycle 09 | 0.000 ± 0.000 |
| Peripheral neuropathy - Treatment Cycle 10 | 0.000 ± 0.000 |
| Peripheral neuropathy - Treatment Cycle 11 | 11.111 ± 19.245 |
| Peripheral neuropathy - Treatment Cycle 12 | 0.000 ± 0.000 |
| Peripheral neuropathy - Treatment Cycle 13 | 0.000 ± NA |
| Peripheral neuropathy - Treatment Cycle 14 | 0.000 ± 0.000 |
| Peripheral neuropathy - Treatment Cycle 15 | 0.000 ± 0.000 |
| Peripheral neuropathy - Follow Up | 0.000 ± NA |
| Peripheral neuropathy - Follow Up 2 | 0.000 ± NA |
| Peripheral neuropathy - Follow Up 3 | 0.000 ± NA |
| Alopecia -Baseline | 16.667 ± 26.726 |
| Alopecia - Treatment Cycle 02 | -3.333 ± 18.417 |
| Alopecia - Treatment Cycle 03 | -12.500 ± 29.502 |
| Alopecia - Treatment Cycle 04 | -13.889 ± 22.285 |
| Alopecia - Treatment Cycle 05 | -8.333 ± 23.570 |
| Alopecia - Treatment Cycle 06 | -12.500 ± 24.801 |
| Alopecia - Treatment Cycle 07 | -5.556 ± 25.092 |
| Alopecia - Treatment Cycle 08 | -5.556 ± 25.092 |
| Alopecia - Treatment Cycle 09 | -11.111 ± 19.245 |
| Alopecia - Treatment Cycle 10 | -11.111 ± 19.245 |
| Alopecia - Treatment Cycle 11 | -11.111 ± 19.245 |
| Alopecia - Treatment Cycle 12 | -11.111 ± 19.245 |
| Alopecia - Treatment Cycle 13 | 0.000 ± NA |
| Alopecia - Treatment Cycle 14 | -16.667 ± 23.570 |
| Alopecia - Treatment Cycle 15 | -16.667 ± 23.570 |
| Alopecia - Follow Up | -33.333 ± NA |
| Alopecia - Follow Up 2 | -33.333 ± NA |
| Alopecia - Follow Up 3 | -33.333 ± NA |
| Pain in chest - Baseline | 31.818 ± 29.951 |
| Pain in chest - Treatment Cycle 02 | 1.667 ± 29.568 |
| Pain in chest - Treatment Cycle 03 | 0.000 ± 29.814 |
| Pain in chest - Treatment Cycle 04 | 2.778 ± 22.285 |
| Pain in chest - Treatment Cycle 05 | 4.167 ± 33.034 |
| Pain in chest - Treatment Cycle 06 | 0.000 ± 25.198 |
| Pain in chest - Treatment Cycle 07 | 5.556 ± 32.773 |
| Pain in chest - Treatment Cycle 08 | -5.556 ± 25.092 |
| Pain in chest - Treatment Cycle 09 | -11.111 ± 19.245 |
| Pain in chest - Treatment Cycle 10 | -11.111 ± 19.245 |
| Pain in chest - Treatment Cycle 11 | -11.111 ± 19.245 |
| Pain in chest - Treatment Cycle 12 | -11.111 ± 19.245 |
| Pain in chest - Treatment Cycle 13 | 0.000 ± NA |
| Pain in chest - Treatment Cycle 14 | -16.667 ± 23.570 |
| Pain in chest - Treatment Cycle 15 | -16.667 ± 23.570 |
| Pain in chest - Follow Up | -33.333 ± NA |
| Pain in chest - Follow Up 2 | -33.333 ± NA |
| Pain in chest - Follow Up 3 | -33.333 ± NA |
| Pain in arm or shoulder -Baseline | 22 ± 27.273 |
| Pain in arm or shoulder -Treatment Cycle 02 | -6.667 ± 31.715 |
| Pain in arm or shoulder -Treatment Cycle 03 | -12.500 ± 36.260 |
| Pain in arm or shoulder -Treatment Cycle 04 | -8.333 ± 35.176 |
| Pain in arm or shoulder -Treatment Cycle 05 | -4.167 ± 45.207 |
| Pain in arm or shoulder -Treatment Cycle 06 | -4.167 ± 41.547 |
| Pain in arm or shoulder -Treatment Cycle 07 | 5.556 ± 25.092 |
| Pain in arm or shoulder -Treatment Cycle 08 | 22.222 ± 40.369 |
| Pain in arm or shoulder -Treatment Cycle 09 | 33.333 ± 57.735 |
| Pain in arm or shoulder -Treatment Cycle 10 | 11.111 ± 50.918 |
| Pain in arm or shoulder -Treatment Cycle 11 | 11.111 ± 50.918 |
| Pain in arm or shoulder -Treatment Cycle 12 | 11.111 ± 50.918 |
| Pain in arm or shoulder -Treatment Cycle 13 | 0.000 ± NA |
| Pain in arm or shoulder -Treatment Cycle 14 | 50.000 ± 70.711 |
| Pain in arm or shoulder -Treatment Cycle 15 | 16.667 ± 23.570 |
| Pain in arm or shoulder - Follow Up | 33.333 ± NA |
| Pain in arm or shoulder - Follow Up 2 | 0.000 ± NA |
| Pain in arm or shoulder - Follow Up 3 | 33.333 ± NA |
| Pain in other parts - Baseline | 25.758 ± 28.971 |
| Pain in other parts - Treatment Cycle 02 | -3.333 ± 23.939 |
| Pain in other parts - Treatment Cycle 03 | -2.083 ± 22.669 |
| Pain in other parts - Treatment Cycle 04 | 2.778 ± 22.285 |
| Pain in other parts - Treatment Cycle 05 | 16.667 ± 25.198 |
| Pain in other parts - Treatment Cycle 06 | -4.167 ± 21.362 |
| Pain in other parts - Treatment Cycle 07 | -5.556 ± 25.092 |
| Pain in other parts - Treatment Cycle 08 | 5.556 ± 32.773 |
| Pain in other parts - Treatment Cycle 09 | -11.111 ± 19.245 |
| Pain in other parts - Treatment Cycle 10 | -11.111 ± 19.245 |
| Pain in other parts - Treatment Cycle 11 | -11.111 ± 19.245 |
| Pain in other parts - Treatment Cycle 12 | -11.111 ± 19.245 |
| Pain in other parts - Treatment Cycle 13 | 0.000 ± NA |
| Pain in other parts - Treatment Cycle 14 | -16.667 ± 23.570 |
| Pain in other parts - Treatment Cycle 15 | -16.667 ± 23.570 |
| Pain in other parts - Follow Up | -33.333 ± NA |
| Pain in other parts - Follow Up 2 | -33.333 ± NA |
| Pain in other parts - Follow Up 3 | -33.333 ± NA |
Collected over Baseline up to approximately 2.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atezolizumab Plus Bevacizumab | 17/23 (73.9%) | 4/23 (17.4%) | 23/23 (100%) |
| Event | Atezolizumab Plus Bevacizumab |
|---|---|
| DeathGeneral disorders | 1/23 |
| MalaiseGeneral disorders | 1/23 |
| Left ventricular dysfunctionCardiac disorders | 1/23 |
| GastroenteritisInfections and infestations | 1/23 |
| PneumoniaInfections and infestations | 1/23 |
| Upper respiratory tract infectionInfections and infestations | 1/23 |
| Platelet count decreasedInvestigations | 1/23 |
| Event | Atezolizumab Plus Bevacizumab |
|---|---|
| ProteinuriaRenal and urinary disorders | 7/23 |
| FatigueGeneral disorders | 6/23 |
| Aspartate aminotransferase increasedInvestigations | 6/23 |
| HypertensionVascular disorders | 6/23 |
| AnaemiaBlood and lymphatic system disorders | 5/23 |
| Urinary tract infectionInfections and infestations | 5/23 |
| Blood thyroid stimulating hormone increasedInvestigations | 5/23 |
| Platelet count decreasedInvestigations | 5/23 |
| Decreased appetiteMetabolism and nutrition disorders | 5/23 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 5/23 |
| Age, Continuous(Years) | Atezolizumab Plus Bevacizumab |
|---|---|
| Mean | 59.8 ± 10.07 |
| Sex: Female, Male(Participants) | Atezolizumab Plus Bevacizumab |
|---|---|
| Female | 13 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | Atezolizumab Plus Bevacizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 23 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Smoking History(Participants) | Atezolizumab Plus Bevacizumab |
|---|---|
| Never | 16 |
| Current | 0 |
| Previous | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Sep 2020 to primary completion in Jan 2022, 16 months.
Results were first posted in Apr 2023, 1 year 2 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 16 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atezolizumab · Bevacizumab
Carcinoma, Non-Small-Cell Lung →